One candidate is for the treatment of renal anemia in dialysis patients and the other is for adult growth hormone deficiency.
TPG Biotech will fund the late-stage clinical development of two drug candidates from JCR Pharmaceuticals: JR-013 and Growject®. Under the terms of the agreement, TPG Biotech will fund the development of the drugs and in return will receive milestone payments, royalties, and warrants to purchase JCR’s common stock.
JR-013 is a recombinant human erythropoietin for the treatment of renal anemia in dialysis patients. The drug was originated by JCR and is currently undergoing Phase II/III studies in Japan.
Growject is currently approved and marketed in Japan to treat short stature in children with growth hormone deficiency and Turner’s syndrome. JCR is extending Growject use to treat adult growth hormone deficiency (AGHD). Clinical studies for AGHD have been completed and application for an approval of this extended use has been filed with the Japanese Ministry of Health, Labor and Welfare.